Bavarian Nordic said the European Commission approved a Type 2 variation for IMVANEX, extending the smallpox/mpox vaccine’s marketing authorization to children aged 2 to under 12 years. This expands the eligible patient population versus prior age limits and supports broader commercialization in the EU. The update is a positive regulatory milestone for the company’s product positioning and near-to-medium term revenue potential.
Bavarian Nordic said the European Commission approved a Type 2 variation for IMVANEX, extending the smallpox/mpox vaccine’s marketing authorization to children aged 2 to under 12 years. This expands the eligible patient population versus prior age limits and supports broader commercialization in the EU. The update is a positive regulatory milestone for the company’s product positioning and near-to-medium term revenue potential.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
